saline-immersion therapeutic endoscopy (SITE) facilitated ESD with a ball-tipped, needle-type ESD knife (Flush Knife-BT (1.5mm), Fujifilm, Tokyo, Japan). The resection site was clipped prophylactically and the lipoma was retrieved with a Roth® net (Steris, Mentor, OH, USA) (Fig. 3-4). No immediate, early or late adverse events occurred. Histopathology confirmed complete resection of an ileal lipoma.

Conclusions Our case demonstrates the usefulness of this technique, particularly when combined with the safe and stable endotherapeutic platform afforded by DBE and the buoyancy facilitated by SITE. To the best of our knowledge this is only the 3rd reported case of ESD for a TI lipoma and the only case to date combining the use of SITE-ESD and DBE.

PTU-65 CYANOACRYLATE-INJECTION ENDOTHERAPY FACILITATED BY DOUBLE-BALLOON ENTEROSCOPY: ENDOSCOPIC MANAGEMENT OF ANASTOMOTIC VARICES BLEEDING

¹Nikolaos Lazaridis*, ¹Alberto Murino, ¹Alexandros Skamnelos, ¹Rocio Chacchi Cahuin, ¹Nikolaos Koukias, ¹Regina Raymond, ²Dalvinder Mandair, ¹Edward J Despott. ¹Royal Free Unit for Endoscopy, The Royal Free Hospital, University College London (UCL) Institute for Liver and Digestive Health, London, UK; ²Neuroendocrine Tumour Unit, Centre for Gastroenterology, ENETS Centre of Excellence, The Royal Free Hospital and University College London (UCL) Institute for Liver and Digestive Health, London, UK

10.1136/gutjnl-2021-BSG.138

Introduction Small bowel varices are an uncommon cause of severe gastrointestinal bleeding. There is no consensus regarding the endoscopic management of these patients. Cyanoacrylate injection endotherapy has been described as a therapeutic alternative in some cases.

Methods A 65-year-old man with a metastatic mid-gut neuroendocrine tumour warranting extensive small-bowel resection presented with life-threatening mid-gut bleeding. A CT enterography (CTE) demonstrated jejunal anastomotic varices, with superior mesenteric vein thrombosis. Without a radiological option for treatment, antegrade double-balloon enteroscopy (DBE) was planned to facilitate cyanoacrylate-injection endotherapy (CIE).

Results During DBE 2 nests of bleeding varices were identified at the anastomosis. DBE CIE (diluted in lipiodol) was successful performed through a wide-bore injection-needle. No immediate or delayed adverse events were reported. A subsequent CTE confirmed successful embolisation of the mid-gut varices. The patient has not bled further during 6-months of follow-up.

Conclusions DBE facilitated CIE of mid-gut varices is effective and safe in carefully selected cases.

PTU-66 MANAGEMENT OF SMALL-BOWEL POLYPS IN PATIENTS WITH PEUTZ-JEGHERS SYNDROME: ISCHAEMIC POLYPECTOMY ASSISTED BY DOUBLE-BALLOON ENTEROSCOPY

¹Nikolaos Lazaridis, ¹Alexandros Skamnelos, ¹Alberto Murino, ^{1,2}Erasmia Vlachou, ¹Nikolaos Koukias, ¹Rocio Chacchi Cahuin*, ¹Sarah Walton, ¹Regina Raymond, ¹Edward J Despott. ¹Royal Free Unit for Endoscopy, The Royal Free Hospital, University College London (UCL) Institute for Liver and Digestive Health, London, UK; ²Department of Gastroenterology and Endoscopy, NIMTS Army Veterans Hospital, Athens, Greece

10.1136/gutjnl-2021-BSG.139

Introduction Ischaemic polypectomy with detachable-snare or endoclips at double-balloon enteroscopy (DBE) is emerging as a promising technique for the minimally-invasive management of small-bowel polyps in patients with Peutz-Jeghers syndrome (PJS).

Methods The aim of our study was to review our experience of ischaemic polypectomies in patients with PJS from July 2017 to November 2020. Demographic, endoscopic, histopathological data were analysed.

Results In this case series, 46 polyps were treated during 9 therapeutic DBEs (6 antegrade and 3 retrograde) performed in 4 patients (3 male and 1 female). Seven polyps >20mm in size required loop ligation with a detachable-snare. The majority of the small bowel polyps (39 lesions) were <20mm and were treated successfully with the double-clipping technique. No immediate or late adverse events occurred. All patients remained asymptomatic during follow-up (mean 19; range 1-48 months). None required subsequent surgery.

Abstract PTU-66 Tabel 1

Age/ Gender	Number of procedures (antero/retro)	Total polyps	Clipping	Detachable snare for polyps >20mm
50/M	2(1/1)	17	17	-
56/M	1(1/-)	14	14	-
29/F	3(1/2)	7	4	3
29/M	3(3/-)	8	4	4

Conclusions Ischaemic polypectomy facilitated by DBE appears to be a safe and effective endotherapeutic option for endotherapy of small-bowel polyps in patients with PJS.

IBD

PMO-1 IDENTIFICATION OF A NOVEL COLONIC MACROPHAGE SIGNATURE IN A SUBSET OF CROHN'S DISEASE PATIENTS

¹Hannah Baer*, ²Elizabeth McDonald, ³Muhammad I Khan, ⁴Umer I Zeeshan, ¹John Cole, ⁵Meera Ramanujam, ¹Robert BJ Nibbs, ¹Simon WF Milling. ¹Institute of Infection, Inflammation and Immunity – University of Glasgow, Glasgow, UK; ²Medical Research Institute – QIMR Berghofer, Brisbane, Australia; ³Gastroenterology Unit – Glasgow Royal Infirmary, Glasgow, UK; ⁴School of Engineering – University of Glasgow, Glasgow, UK; ⁵Boehringer Ingelheim Pharmaceuticals Inc, Immunology and Respiratory Diseases Research, Ridgefield, USA

10.1136/gutjnl-2021-BSG.140

Introduction Inflammatory bowel diseases (IBD) are conditions characterised by chronic gastrointestinal inflammation resulting from abnormal immune responses against gut microbiota. Crohn's disease (CD) is one of the two common forms of IBD which can manifest as inflammation anywhere along the gastrointestinal tract, causing potentially life-threatening complications. A wide range of immunomodulatory therapies are available for IBD treatment. However response rates are often suboptimal and many patients still require resective surgery. Therapeutic outcomes could be significantly improved by identifying biomarkers that predict treatment responses in CD patients and by developing a deeper understanding of the different molecular mechanisms that drive inflammation.

Methods Transcriptomic analysis using bulk RNA sequencing was performed on inflamed CD ($n_{CD}=4$) and non-IBD control ($n_{NC}=6$) colonic biopsies taken during colonoscopy. Raw gene expression data were processed using an RNA sequencing exploration pipeline, and immune system-associated genes and pathways were selected to assess immunopathotypes. To validate findings, publicly deposited gene expression datasets were used and targets of interest quantified using immunohistochemistry (IHC) ($n_{CD}=23$ and $n_{NC}=22$).

Results Our transcriptomic analyses identified four enriched clusters linked to different immune pathways and cell types in distinct subsets of CD patients with ongoing inflammation. Validation in a larger gene expression dataset highlighted an immune cluster characterised by macrophage and neutrophil activation and infiltration. IHC analysis demonstrated the co-localisation of proteins encoded by signature genes with the macrophage marker CD68, suggesting that macrophages are the key cell type. Our findings indicated the presence of two macrophage subsets that are potentially interacting to perpetuate inflammation in a subgroup of CD patients. The clinical relevance of this signature is currently still being evaluated to explore if it is a suitable biomarker of a distinct CD immunopathotype.

Conclusions Overall our data shows a unique macrophage-associated signature to be enriched in a subset of CD patients, the potential clinical utility of which is currently under investigation.

PMO-2 CAN WE PREDICT CMV COLITIS WITH HAEMOGRAM-BASED INFLAMMATORY INDICES?

¹Arda Yavuz*, ¹Kubra Akan, ²Muhammet Mikdat Akbas, ²Busra Gulec, ¹Celal Ulasoglu, ¹Ilyas Tuncer. ¹Istanbul Medeniyet University, Department of Gastroenterology, Istanbul, Türkiye; ²Istanbul Medeniyet University, Department of Internal Medicine, Istanbul, Türkiye

10.1136/gutjnl-2021-BSG.141

Introduction This study aims to assess the predictive value of indices as systemic immune-inflammation index (SII), neutrophil-lymphocyte ratio (NLR) and monocyte/lymphocyte ratio (MLR) on presence of active CMV infection in UC patient.

Methods We retrospectively reviewed colonoscopy reports of UC patients between January 2011 and January 2021. These indices are derived from the CBC parameters. CMV colitis was diagnosed from PCR of colonic tissue. The patients with CMV colitis were treated with gancyclovir for 21 days. Statistical analyses were performed using SPSS. Receiver operating characteristic (ROC) curve analysis was used to determine the cut-off values for predicting CMV colitis.

Results A total of 269 UC patients were involved. 19 (7.1%) patients had documented CMV colitis. CMV patients had pancolitis ($n=11$, 57.9%) and left-sided colitis in 8(42.1%). The drugs used were mesalazine monotherapy ($n=9$), azathioprine ($n=6$) and anti-TNF therapy ($n=4$). The control group consisted of 250 UC patients without active CMV. This group mostly had left-sided colitis ($n=128$), while the number of proctitis was 40 and pancolitis in 82.

There were significant differences between CMV PCR(+) and CMV PCR (-) cases by means of SII ($p=0,037$), NLR ($p=0,040$) and MLR ($p=0,016$) indices. Moreover, there was no significant superiority between SII, NLR, and MLR. According to the ROC curve analysis, the best cut-off MLR value to differentiate between patients with CMV colitis from UC was >0.43 (Sens:36.8 ;Spec:89.1 ; PPV:21.2 ; NPV:94.7),

Abstract PMO-2 Table 1 Comparison of indices and cut off values according to CMV PCR

	CMV PCR (+)	CMV PCR(-)	P value
Total (n=269)	19	250	NA
Gender F/M	5/14	105/145	0.169
SII<900	6	135	0.036*
SII>900	13	104	
NLR<3.1	6	138	0.027*
NLR>3.1	13	101	
MLR <0.43	12	213	0.005*
MLR >0.43	7	26	

NA : not available SII : systemic inflammation index NLR : neutrophil lymphocyte ratio MLR : monocyte lymphocyte ratio

best cut-off NLR value was >3.1 (Sens:68.4 ;Spec:57.7 ; PPV:11.4 ; NPV:95.8), and best cut-off SII value was >900 (Sens:68.4 ;Spec:52.3 ; PPV:11.1 ; NPV:95.7) (Table 1).

Conclusions This is the first report to demonstrate that SII, NLR, MLR may predict superinfection of CMV colitis in UC patients. The cut-off values were 900, 3.1 and 0.43 for systemic inflammation index, NLR and MLR, respectively. Thus, CMV complicating UC seems to result with higher inflammatory indices. Large scale, prospective studies are needed for further conclusion.

PMO-3 THE SPIT STUDY: CREATING A SALIVA BASED EPIGENETIC BIOMARKER PANEL TO DIAGNOSE CROHN'S DISEASE

¹Timothy Stone*, ¹Vanessa Ward, ²Avi Rosenfeld, ¹Aine Hogan, ³Ami Ya'acov, ³Aviya Hoyda, ³Sapir Liansky, ¹Ho K M A, ¹Paul Wolfson, ¹Ash Wilson, ³Ariella Bar-Gal Shitrit, ¹Elena Schiff, ¹Adam Levine, ⁴The SPIT Study Group, ^{1,5}Laurence Lovat. ¹Division of Surgery and Interventional Science, University College London, London, UK; ²Department of Computer Science, Jerusalem College of Technology, Jerusalem, Israel; ³Digestive Diseases Institute, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; ⁴The SPIT Study Group; ⁵Department of Gastrointestinal Services, University College London Hospitals NHS Foundation Trust, London, UK

10.1136/gutjnl-2021-BSG.142

Introduction The SPIT study (ISRCTN11921553) aims to investigate the methylation changes in saliva that result from Crohn's disease with the ultimate aim of developing a diagnostic biomarker.

Aims and Methods We selected 192 volunteers, 96 with Crohn's Disease and 96 controls. These were drawn from participants in the SPIT study and were carefully chosen so that differences in sex ratio and average age were as small as possible between the two groups. All participants completed a questionnaire on relevant lifestyle factors and provided a fasting saliva sample. Stringent DNA quality-control was performed. Following DNA extraction and bisulfite conversion, samples were analysed using the 850k Infinium methylation EPIC array.

Multiple quality-control metrics were analysed. This led to removal of 38 samples, leaving 154 samples for differential methylation analysis. Stringent batch-effect removal was applied by calculating the residuals of a batch-fitted linear model on each locus. Differential methylation analysis was